Filters

Fabio Galetta, Ferdinando Franzoni, Giulia Cervetti, Francesco Regoli, Poupak Fallahi, Leonardo Tocchini, Angelo Carpi, Alessandro Antonelli, Mario Petrini, Gino Santoro

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2010;64(4):259-63

Full Text

Abstract

Radioprotectants: current status and new directions.

David J Grdina, Jeffrey S Murley, Yasushi Kataoka

Oncology 2003;63 Suppl 2():2-10

Full Text

Abstract

Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.

D Gandara, M L Tetef, T W Synold, W Chow, L Leong, K Margolin, R Morgan, J Raschko, S Shibata, G Somlo, Y Yen, S Groshen, K Johnson, H J Lenz, J H Doroshow

Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1569-76

Full Text

Abstract

Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects.

H Zheng, X Huang, Q Zhang, S D Katz

Kidney international 2006;69(4):679-84

Free Full Text

Abstract

Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.

H Kaiserová, G J M den Hartog, T Simůnek, L Schröterová, E Kvasnicková, A Bast

British journal of pharmacology 2007;149(7):920-30

Free Full Text

Abstract

Can anthracycline therapy for pediatric malignancies be less cardiotoxic?

Joy M Fulbright, Winston Huh, Pete Anderson, Joya Chandra

Current oncology reports 2011;12(6):411-9

Full Text

Abstract

Results: 1 – 15 / 15

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Razoxane""[mesh_terms]

Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.

Cutaneous vascular patterns in psoriasis.

Dexrazoxane use in the prevention of anthracycline extravasation injury.

Cardioprotective interventions for cancer patients receiving anthracyclines.

Prevention of anthracycline-induced cardiotoxicity in children: the evidence.

Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.

Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects.

Cardiotoxicity of cytotoxic drugs.

In vitro and in vivo study on the antioxidant activity of dexrazoxane.

Radioprotectants: current status and new directions.

Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.

Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects.

Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.

Can anthracycline therapy for pediatric malignancies be less cardiotoxic?

Results for
""Razoxane""[mesh_terms]